Speech-Language Pathologists in Beaver, OH Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Mindie Bond, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3815 Coal Dock Rd, Beaver, OH 45613 Phone: 740-708-0781 |
Jennifer Lee Oakley Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1170 Tile Mill Rd, Beaver, OH 45613 Phone: 740-226-6402 |
News Archive
Scientists use innovative exome sequencing strategy to identify new gene associated with ALS
Using an innovative exome sequencing strategy, a team of international scientists led by John Landers, PhD, at the University of Massachusetts Medical School has shown that TUBA4A, the gene encoding the Tubulin Alpha 4A protein, is associated with familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease.
'Substantial' variation from state to state in hospital safety records
Arizona, California, Illinois and Ohio scored the best marks for hospital care in a new report ... The differences between states are "substantial,'' says Evan Marks, a lead author. "For instance, in Alabama you have a 42% higher risk of dying from a heart attack in a hospital than in Arizona."
Balance test can temporarily alleviate common symptom in schizophrenia patients
A common symptom of schizophrenia - not knowing that you're ill - can be temporarily alleviated using a balance test that stimulates part of the brain with cold water, an exploratory study at the Centre for Addiction and Mental Health has shown.
Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon
A study published in PLOS Neglected Tropical Diseases, by Mirdad Kazanji, of the Centre International de Recherches Medicales de Franceville in Gabon, and the Institut Pasteur de la Guyane in French Guiana, suggests that 30 years after the first epidemiological survey of the seroprevalence of Human T-cell lymphotropic virus type 1 (HTLV-1) infections in Gabon, the country remains highly endemic, with a seroprevalence of 7.3%.
Aegerion third quarter net loss increases to $6.2 million
Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the third quarter ended September 30, 2010.
› Verified 5 days ago